Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Summary
The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.
Official title: An Open-label Study Evaluating the Safety and Preliminary Clinical Activity of Cizutamig in Patients With Refractory Seropositive Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2025-06-23
Completion Date
2027-06
Last Updated
2026-01-12
Healthy Volunteers
No
Conditions
Interventions
Cizutamig
Cizutamig will be administered per the dose escalation cohort
Cizutamig
Cizutamig will be administered per the dose escalation cohort
Locations (1)
Wuhan Union Hospital
Wuhan, Hubei, China